Ocular Therapeutix OCUL Income Statement
| FY'25 | FY'24 | FY'23 | FY'22 | ||
|---|---|---|---|---|---|
| $51.95M-18.5% | $63.72M+9.0% | $58.44M+13.5% | $51.49M+18.3% | ||
| $6.57M+16.9% | $5.63M+6.5% | $5.28M+16.3% | $4.54M+3.0% | ||
| $45.38M-21.9% | $58.1M+9.3% | $53.16M+13.2% | $46.95M+20.0% | ||
| 87.3%-3.8pp | 91.2%+0.2pp | 91%-0.2pp | 91.2%+1.3pp | ||
| $197.1M+54.4% | $127.64M+109% | $61.06M+14.2% | $53.46M+6.7% | ||
| $53.92M+29.7% | $41.59M+2.6% | $40.55M+1.6% | $39.92M+13.4% | ||
| $64.38M+6.1% | $60.65M+78.7% | $33.94M+5.3% | $32.22M+1.1% | ||
| $321.97M+36.7% | $235.5M+67.2% | $140.83M+8.2% | $130.15M+7.1% | ||
| -$270.02M-57.2% | -$171.78M-109% | -$82.38M-4.7% | -$78.65M-0.8% | ||
| -519.8%-250pp | -269.6%-129pp | -141%+11.8pp | -152.7%+26.6pp | ||
| $11.83M-12.8% | $13.58M+19.8% | $11.34M+61.4% | $7.02M+5.3% | ||
| $4.08M— | —— | —— | $7.62M-89.3% | ||
| -$265.94M-37.4% | -$193.51M-140% | -$80.74M-13.7% | -$71.04M-984% | ||
| -511.9%-208pp | -303.7%-166pp | -138.1%-0.2pp | -138%-123pp | ||
| -$1.42-13.6% | -$1.25-8.7% | -$1.15-12.7% | -$1.02-7.4% | ||
| -$265.69M-58.2% | -$168M-112% | -$79.4M-3.7% | -$76.55M-1.2% | ||
| -511.4%-248pp | -263.6%-128pp | -135.9%+12.8pp | -148.7%+25.1pp | ||
| -$270.02M-57.2% | -$171.78M-109% | -$82.38M-4.7% | -$78.65M-0.8% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What is Ocular Therapeutix's revenue?
- Ocular Therapeutix (OCUL) generated $52.0M in revenue over the trailing twelve months, down 12.8% year over year.
- Is Ocular Therapeutix profitable?
- Ocular Therapeutix is not currently profitable: it reported a net loss of $290.5M over the trailing twelve months, a -558.2% net margin.
- What are Ocular Therapeutix's profit margins?
- Gross margin is 87.2% and operating margin is -575.4%, with a -558.2% net margin.
- What is Ocular Therapeutix's earnings per share?
- Ocular Therapeutix's diluted EPS over the trailing twelve months is $-1.44.
- Where does Ocular Therapeutix's income statement data come from?
- Every line is extracted from Ocular Therapeutix's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
